Karen Mueller Email

VP Translational Science . GentiBio

Current Roles

Employees:
102
Revenue:
$15.8M
About
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.
GentiBio Address
150 Cambridgepark Drive
Cambridge, MA
USA
GentiBio Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.